1-3 of 3
Greta Lozano-Ortega
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation

Clara Chen, PhD BS, MS, Philippe Armand, MD PhD, Basia Rogula, Karissa Johnston, Derek Peterson, Joseph M Connors, MD, Greta Lozano-Ortega, MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 4761.
https://doi.org/10.1182/blood-2019-122302
Published: 2019
Journal Articles

Incremental Survival with Nivolumab Relative to Standard of Care in Classical Hodgkin Lymphoma: A Canadian Analysis

Greta Lozano-Ortega, MSc, Basia Rogula, Karissa Johnston, Julie Villeneuve, Andriy Moshyk, Heather O'Brien, Clara Chen, PhD BS, MS, Joseph M. Connors, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5894.
https://doi.org/10.1182/blood-2018-99-111278
Published: 2018
Journal Articles

Cost Effectiveness of Nivolumab for the Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma (cHL) after Failure of Autologous Stem Cell Transplantation (ASCT) and Treatment with Brentuximab Vedotin (BV) Treatment in Australia

Marcus Tan, BPharm, Greta Lozano-Ortega, MSc, Shelagh Szabo, MSc, Karissa Johnston, PhD, Joseph M Connors, MD, Clara Chen, PhD BS, MS, Hansoo Kim
Journal: Blood
Blood (2017) 130 (Supplement 1): 2166.
https://doi.org/10.1182/blood.V130.Suppl_1.2166.2166
Published: 2017